Head-To-Head Contrast: InspireMD (NYSE:NSPR) & Nyxoah (NASDAQ:NYXH)

InspireMD (NYSE:NSPR) and Nyxoah (NASDAQ:NYXH) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares InspireMD and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InspireMD	-413.96%	-69.42%	-57.68%
Nyxoah	-313.03%	-153.98%	-68.17%

Earnings and Valuation

This table compares InspireMD and Nyxoah”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InspireMD	$10.84 million	2.83	-$19.92 million	($0.64)	-1.03
Nyxoah	$21.66 million	1.57	-$101.92 million	($1.98)	-0.44

InspireMD has higher earnings, but lower revenue than Nyxoah. InspireMD is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

InspireMD has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500.

Insider & Institutional Ownership

44.8% of InspireMD shares are owned by institutional investors. 25.0% of InspireMD shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for InspireMD and Nyxoah, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InspireMD	0	0	3	0	3.00
Nyxoah	1	1	2	0	2.25

InspireMD presently has a consensus target price of $4.50, suggesting a potential upside of 582.85%. Nyxoah has a consensus target price of $3.55, suggesting a potential upside of 304.52%. Given InspireMD’s stronger consensus rating and higher probable upside, equities analysts clearly believe InspireMD is more favorable than Nyxoah.

Summary

InspireMD beats Nyxoah on 10 of the 14 factors compared between the two stocks.

About InspireMD

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.